NAS:HEPA (USA) Also trade in: Germany

Hepion Pharmaceuticals Inc

$ 2.51 0.01 (0.4%)
Volume: 133,724 Avg Vol (1m): 885,853
Market Cap $: 8.67 Mil Enterprise Value $: 6.60 Mil
P/E (TTM): 0.00 P/B: 0.00
Earnings Power Value -7.18
Net Current Asset Value -28.44
Tangible Book -24.72
Projected FCF 0
Median P/S Value 0
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 3.2/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.64
Cash-To-Debt range over the past 10 years
Min: 0.64, Med: 10000, Max: 10000
Current: 0.64
0.64
10000
Debt-to-Equity 4.09
Debt-to-Equity range over the past 10 years
Min: -2.66, Med: 0.45, Max: 4.09
Current: 4.09
-2.66
4.09
Debt-to-EBITDA -0.21
Debt-to-EBITDA range over the past 10 years
Min: -0.21, Med: -0.1, Max: -0.1
Current: -0.21
-0.21
-0.1
Altman Z-Score -17.20
DISTRESS
GREY
SAFE
WACC vs ROIC %
ROIC 0%
WACC 6.82%

Profitability & Growth : 1/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
ROE % -899.26
ROE range over the past 10 years
Min: -8771.94, Med: -519.6, Max: -287.03
Current: -899.26
-8771.94
-287.03
ROA % -91.37
ROA range over the past 10 years
Min: -505.84, Med: -172.43, Max: -71.11
Current: -91.37
-505.84
-71.11
ROC (Joel Greenblatt) % -6681.63
ROC (Joel Greenblatt) range over the past 10 years
Min: -29188, Med: -28220.13, Max: -6681.63
Current: -6681.63
-29188
-6681.63
3-Year Total EBITDA Growth Rate -1.50
3-Year EBITDA Growth Rate range over the past 10 years
Min: -367.3, Med: -40.6, Max: 39.5
Current: 39.5
-367.3
39.5
3-Year EPS w/o NRI Growth Rate 44.60
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: -1201.6, Med: 9.8, Max: 44.6
Current: 44.6
-1201.6
44.6

Ratios

Current vs industry vs history
EV-to-EBIT -0.53
EV-to-EBIT range over the past 10 years
Min: -9.26, Med: 0, Max: 0.5
Current: -0.53
-9.26
0.5
EV-to-EBITDA -0.53
EV-to-EBITDA range over the past 10 years
Min: -9.26, Med: 0, Max: 0.5
Current: -0.53
-9.26
0.5
Current Ratio 0.55
Current Ratio range over the past 10 years
Min: 0.02, Med: 1.62, Max: 24.52
Current: 0.55
0.02
24.52
Quick Ratio 0.55
Quick Ratio range over the past 10 years
Min: 0.02, Med: 1.62, Max: 24.52
Current: 0.55
0.02
24.52

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -67.70
3-Year Share Buyback Rate range over the past 10 years
Min: -67.7, Med: -65.4, Max: -13.3
Current: -67.7
-67.7
-13.3

Valuation & Return

Current vs industry vs history
Earnings Yield (Joel Greenblatt) % -193.52
Earnings Yield (Greenblatt) range over the past 10 years
Min: -99999999.99, Med: 0, Max: 46068.88
Current: -193.52
-99999999.99
46068.88

» HEPA's 30-Y Financials

Financials (Next Earnings Date: )

» Interactive Chart

Peter Lynch Chart

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:HEPA

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare XSAT:EUCI TSXV:VXL OTCPK:PTEO OTCPK:GOVX OSL:ABT OTCPK:TNTY ASX:ACL WAR:RDG OTCPK:GLPH OTCPK:AMBS OTCPK:OBMP OTCPK:TIKRF BOM:532871 OTCPK:RSPI TSXV:IBT OTCPK:BTHE OTCPK:MNTM OTCPK:PRTX TSXV:IOT LSE:PYC
Traded in other countries 336P.Germany
Address 399 Thornall Street, First Floor, Edison, NJ, USA, 08837
ContraVir Pharmaceuticals Inc is a US-based biopharmaceutical company which is engaged in the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus (HBV) infections. The company focuses on developing two compounds to treat HBV infection i.e. CMX157 which is a potent oral prodrug of tenofovir and CMX157 which is novel drug candidate designed for the treatment of HBV infection. In addition, the company is developing an antiviral asset known as FV-100. FV-100 which is a small molecule compound being developed for the prevention of post-herpetic neuralgia (PHN) and treatment of herpes zoster infection and acute zoster-associated pain.

More Statistics

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 0
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA N
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N